ARTICLE | Company News
Acorda Therapeutics, Inc., Neuronex deal
December 24, 2012 8:00 AM UTC
Acorda completed its acquisition of Neuronex, which is developing a nasal spray formulation of diazepam for epilepsy, with a closing payment of $6.8 million. Acorda made an initial payment of $2 million to Neuronex in 1Q12 and an additional payment of $1.5 million to fund R&D activities prior to deal close. ...